Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 88INDUSTRY 74NIH 17FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Neoplasm Metastasis 2Motor Activity 2Thoracic Neoplasms 1Stroke 1Prostatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neurofibromatosis 2 1Neoplasms by Site 1Neoplasms 1Myasthenia Gravis 1Melanoma 1Lymphoproliferative Disorders 1Lung Diseases 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Diabetes Mellitus 1Coronary Disease 1Condylomata Acuminata 1Colorectal Neoplasms 1Carcinoma, Bronchogenic 1Breast Neoplasms, Male 1

Interventions

Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × FED × Liver Neoplasms × Clear all
NCT00216437 2007-11-12

Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma

James A. Haley Veterans Administration Hospital

Phase 1 Terminated
30 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡